CA-ARCULES
11.2.2020 17:32:06 CET | Business Wire | Press release
Arcules , leading innovators in integrated video and access control cloud services, today announced the commercial availability of the Arcules-XProtect Hybrid™ VMS Solution in North America and Europe. The solution represents a combination of the Arcules Video Surveillance as a Service (VSaaS) integrated with Milestone XProtect Corporate on-premise video management software (VMS). The result is a flexible and feature-rich hybrid video surveillance solution ideal for organizations looking to centralize their dispersed video surveillance operations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200211005274/en/
With Arcules-XProtect Hybrid VMS Solution, Milestone XProtect customers can deploy remote sites quickly, with minimal IT resources and downtime while still benefiting from the strong capabilities of XProtect on-premise VMS. Additionally, Arcules’ intuitive platform provides sites and cameras connected to Arcules VSaaS an underlying cloud infrastructure such as compatibility between sites, low video latency, data encryption, redundancy, streamlined maintenance with automatic updates, and easy onboarding.
“Milestone resellers and end customers are planning their deployment to take advantage of the many benefits of cloud computing. This integration gives Milestone XProtect Corporate customers a new hybrid cloud computing deployment option,” said Bjørn Skou Eilertsen, CTO of Milestone Systems. “The typical Milestone XProtect Corporate user has many branch offices of different sizes and locations. Enabling this hybrid deployment option can allow them to simplify large scale deployments. After the Arcules system is Interconnected the user can utilize these Arcules connected cameras with the advanced XProtect Corporate product capabilities.”
The Arcules-XProtect Hybrid VMS Solution uses Milestone Interconnect™ technology to combine the hyper-scalability and licensing flexibility of Arcules cloud service with the feature-rich video management functions of XProtect Corporate. The combination of these advanced technologies provides uniform access to live video, recordings and alarms across cameras physically connected on-premise and virtually connected via the Arcules cloud, through XProtect Smart Client, XProtect Smart Wall, and the web and mobile clients.
Organizations with distributed locations such as healthcare, retail, corporate campuses and education, and utility environments all benefit from high-performance cloud services to provide real-time insight in the event of an incident in remote areas. The Arcules-XProtect Hybrid VMS Solution also adds value to monitoring stations and law enforcement organizations that use XProtect Corporate as their VMS platform. Such organizations can now access cameras and customers subscribed to the Arcules cloud service directly from their on-premise XProtect system.
“The Arcules-XProtect Hybrid VMS Solution is an ideal solution for businesses looking to expand their surveillance operation across geographically dispersed locations,” said Arcules CEO Andreas Pettersson. “These businesses can enjoy the strong capabilities of on-premise VMS while reducing their capital investment. The solution also enables organizations to better manage their operational costs as a result of flexible pricing schemes and minimal hardware requirements.”
The Arcules-XProtect Hybrid VMS Solution regional availability outside of North America and Europe is based on market demand conditioned by datacenter availability and/or the possibility to utilize data centers in other regions.
Arcules will demonstrate the solution in booth #809 at the MIPS 2020 Conference , February 17-19, at the Gaylord Texan in Grapevine, TX as well as in Arcules booth #31081 and Milestone booth #18053 during the 2020 ISC West Conference and Expo , March 17-20, at the Sands Expo in Las Vegas.
About Arcules
Arcules, a Canon Group company, addresses the unmet need of modern enterprises for integrated cloud-based video surveillance, access control and analytics. Using the latest developments in cloud, artificial intelligence and machine learning, Arcules combines previously untapped video monitoring data with sensor data and analytics to deliver actionable insights that ultimately drive better business decisions, optimize operations and improve safety. Arcules is headquartered in Irvine, Calif. Visit www.arcules.com for more information and follow us on LinkedIn , Facebook , and Twitter .
About Milestone Systems
Milestone Systems is a leading provider of open platform video management software; technology that helps the world see how to ensure safety, protect assets and increase business efficiency. Milestone enables an open platform community that drives collaboration and innovation in the development and use of network video technology, with reliable and scalable solutions that are proven in more than 500,000 installations worldwide. Founded in 1998, Milestone is a stand-alone company in the Canon Group. For more information visit: http://www.milestonesys.com . For news and other press releases, visit our Newsroom . Click here for information on Trademarks.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200211005274/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom